Key Highlights

  • Third quarter Net Income was USD 77.8 million, including the gain on divesting Assets tied to the strategic transaction.
  • The company closed a USD 100 million strategic transaction and ended September with USD 80.6 million in cash.
  • Total assets were about USD 114 million, liabilities USD 42 million and shareholders' Equity USD 73 million.
  • The company plans to submit an NDA for ifetroban in Duchenne muscular dystrophy, based on Phase 2 data.

Cumberland Pharmaceuticals (NASDAQ:CPIX) reported third quarter 2026 results as its first full quarter as a development-focused company, following the closing of a USD 100 million strategic transaction. The Earnings data show a loss of USD 0.07 per share and Revenue of USD 2.16 million, with no analyst estimates available for comparison.

Net income for the quarter was USD 77.8 million. It included the gain on divestiture of assets associated with the transaction, whose revenues and expenses continued to be classified as discontinued operations, along with ongoing Research and Development Investment supported by the remaining general and administrative expenses.

At September 30 the company had approximately USD 114 million in total assets, including USD 80.6 million in cash and cash equivalents. Liabilities totaled USD 42 million and shareholders' equity was USD 73 million. The company said the USD 100 million of proceeds at closing strengthened its balance sheet, simplified its Business model and let it concentrate resources on its clinical pipeline.

Ifetroban in Duchenne Muscular Dystrophy

The company plans to submit a New Drug Application for ifetroban in Duchenne muscular dystrophy. The submission is to be supported by data from the Phase 2 FIGHT DMD trial, which showed a statistically significant 5.4 percentage point improvement in left ventricular ejection fraction in the high-dose group compared with a control group combining placebo-treated patients and propensity score-matched natural history patients, with a p-value of 0.002.

The application is also to include long-term data from the ongoing open-label extension, preclinical data published in the Journal of the American Heart Association, Manufacturing information and a safety database of more than 1,400 subjects across about 30 clinical studies. Through up to 36 months of treatment across the Phase 2 trial and the extension, the company reports ifetroban has maintained a favorable safety profile in patients with Duchenne muscular dystrophy, with no treatment-related serious adverse events or new safety concerns.

Systemic Sclerosis and Other Studies

The company announced top-line results from its Phase 2a ASSIST-SSc trial evaluating ifetroban in patients with systemic sclerosis, an autoimmune disease characterized by diffuse fibrosis of the skin and internal organs for which no therapy approved for the underlying condition is described. Its Phase 2 programs are also evaluating ifetroban in idiopathic pulmonary fibrosis and cancer metastasis.

Items to Follow

The timing of the Duchenne application, further details on the systemic sclerosis results and the use of the cash balance are the items to follow. Total assets, liabilities and equity at September 30 are the Balance Sheet markers, and the cash figure is large relative to the reported loss per share.